home.social

#antivirals — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #antivirals, aggregated by home.social.

fetched live
  1. Low levels of replicating Epstein-Barr viruses might be the main driver of the autoimmune condition multiple sclerosis. This may mean that targeting them would be as effective as suppressing the… #science #multiplesclerosis #antivirals

    newscientist.com/article/25795

    Posted into FLIPBOARD EXCHANGE FEED 🗞️ @flipboard-exchange-feed-Econopass

  2. Low levels of replicating Epstein-Barr viruses might be the main driver of the autoimmune condition multiple sclerosis. This may mean that targeting them would be as effective as suppressing the… #science #multiplesclerosis #antivirals

    newscientist.com/article/25795

    Posted into FLIPBOARD EXCHANGE FEED 🗞️ @flipboard-exchange-feed-Econopass

  3. Low levels of replicating Epstein-Barr viruses might be the main driver of the autoimmune condition multiple sclerosis. This may mean that targeting them would be as effective as suppressing the… #science #multiplesclerosis #antivirals

    newscientist.com/article/25795

    Posted into FLIPBOARD EXCHANGE FEED 🗞️ @flipboard-exchange-feed-Econopass

  4. A Sea Anemone Uses CARDIB to Fight Viruses—and It’s Even More Bizarre Than It Sounds

    Floating outside the salt marsh silt it usually nestles in, the starlet sea anemone (Nematostella vectensis) looks a…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Science #antivirals #marineanimals #MARINECONSERVATION #medicaldiscoveries
    newsbeep.com/us/739902/

  5. Okogen acquires ranpirnase IP portfolio from Orgenesis, strengthening its antiviral pipeline for eye infections, respiratory viruses, and emerging infectious diseases. Lead candidate OKG-0303 targets unmet needs in conjunctivitis treatment. #Biotech #Antivirals

  6. Okogen acquires ranpirnase IP portfolio from Orgenesis, strengthening its antiviral pipeline for eye infections, respiratory viruses, and emerging infectious diseases. Lead candidate OKG-0303 targets unmet needs in conjunctivitis treatment. #Biotech #Antivirals

  7. Okogen acquires ranpirnase IP portfolio from Orgenesis, strengthening its antiviral pipeline for eye infections, respiratory viruses, and emerging infectious diseases. Lead candidate OKG-0303 targets unmet needs in conjunctivitis treatment. #Biotech #Antivirals

  8. Okogen acquires ranpirnase IP portfolio from Orgenesis, strengthening its antiviral pipeline for eye infections, respiratory viruses, and emerging infectious diseases. Lead candidate OKG-0303 targets unmet needs in conjunctivitis treatment. #Biotech #Antivirals

  9. NanoViricides' NV-387 receives FDA Orphan Drug Designation for measles treatment, unlocking tax credits and market exclusivity. The broad-spectrum antiviral advances toward Phase II trials. #Biotech #Antivirals

  10. NanoViricides' NV-387 receives FDA Orphan Drug Designation for measles treatment, unlocking tax credits and market exclusivity. The broad-spectrum antiviral advances toward Phase II trials. #Biotech #Antivirals

  11. NanoViricides' NV-387 receives FDA Orphan Drug Designation for measles treatment, unlocking tax credits and market exclusivity. The broad-spectrum antiviral advances toward Phase II trials. #Biotech #Antivirals

  12. NanoViricides' NV-387 receives FDA Orphan Drug Designation for measles treatment, unlocking tax credits and market exclusivity. The broad-spectrum antiviral advances toward Phase II trials. #Biotech #Antivirals

  13. NanoViricides to present broad-spectrum antiviral pipeline at D. Boral Capital Global Conference in NYC on May 7. Lead candidate NV-387 completed Phase I trials with zero adverse events. #Biotech #Antivirals

  14. NanoViricides to present broad-spectrum antiviral pipeline at D. Boral Capital Global Conference in NYC on May 7. Lead candidate NV-387 completed Phase I trials with zero adverse events. #Biotech #Antivirals

  15. NanoViricides to present broad-spectrum antiviral pipeline at D. Boral Capital Global Conference in NYC on May 7. Lead candidate NV-387 completed Phase I trials with zero adverse events. #Biotech #Antivirals

  16. NanoViricides to present broad-spectrum antiviral pipeline at D. Boral Capital Global Conference in NYC on May 7. Lead candidate NV-387 completed Phase I trials with zero adverse events. #Biotech #Antivirals

  17. NanoViricides advances broad-spectrum antiviral NV-387 following Andes hantavirus incident. Phase I trial completed successfully; animal models show efficacy against COVID, RSV, influenza, and monkeypox. #Biotech #Antivirals

  18. NanoViricides advances broad-spectrum antiviral NV-387 following Andes hantavirus incident. Phase I trial completed successfully; animal models show efficacy against COVID, RSV, influenza, and monkeypox. #Biotech #Antivirals

  19. NanoViricides advances broad-spectrum antiviral NV-387 following Andes hantavirus incident. Phase I trial completed successfully; animal models show efficacy against COVID, RSV, influenza, and monkeypox. #Biotech #Antivirals

  20. NanoViricides advances broad-spectrum antiviral NV-387 following Andes hantavirus incident. Phase I trial completed successfully; animal models show efficacy against COVID, RSV, influenza, and monkeypox. #Biotech #Antivirals

  21. Excited to share our paper in Journal of Medicinal #Chemistry exploring carbobicyclic nucleoside analogues as potential #antivirals!

    We swapped the ribose oxygen for a carbon in nucleoside analogues and explored this novel scaffold.

    From our library, several compounds showed activity against #HCV, #HSV, #influenza, and #RSV. One uracil-based analogue stood out by inhibiting multiple viruses like #flu and HCV. Modeling suggests it “locks” the viral active site instead of being incorporated into RNA.

    What really surprised us: nucleobases with known antiviral effects (like NHC from molnupiravir) didn’t work in our scaffold—but unmodified uracil did. The scaffold itself changes how these molecules behave.

    Encouragingly, these compounds phosphorylate efficiently in cells without needing prodrugs, don't inhibit human polymerases, and our #synthesis is efficient: 28 pyrimidine and 35 purine analogues from just two intermediates in under 10 steps.

    Huge thanks to all collaborators and colleagues who made this work possible!

    pubs.acs.org/doi/10.1021/acs.j

    J. Med. Chem. 2026, 69, 5, 5501–5539.

    #research #science #drug

  22. Excited to share our paper in Journal of Medicinal #Chemistry exploring carbobicyclic nucleoside analogues as potential #antivirals!

    We swapped the ribose oxygen for a carbon in nucleoside analogues and explored this novel scaffold.

    From our library, several compounds showed activity against #HCV, #HSV, #influenza, and #RSV. One uracil-based analogue stood out by inhibiting multiple viruses like #flu and HCV. Modeling suggests it “locks” the viral active site instead of being incorporated into RNA.

    What really surprised us: nucleobases with known antiviral effects (like NHC from molnupiravir) didn’t work in our scaffold—but unmodified uracil did. The scaffold itself changes how these molecules behave.

    Encouragingly, these compounds phosphorylate efficiently in cells without needing prodrugs, don't inhibit human polymerases, and our #synthesis is efficient: 28 pyrimidine and 35 purine analogues from just two intermediates in under 10 steps.

    Huge thanks to all collaborators and colleagues who made this work possible!

    pubs.acs.org/doi/10.1021/acs.j

    J. Med. Chem. 2026, 69, 5, 5501–5539.

    #research #science #drug

  23. Excited to share our paper in Journal of Medicinal #Chemistry exploring carbobicyclic nucleoside analogues as potential #antivirals!

    We swapped the ribose oxygen for a carbon in nucleoside analogues and explored this novel scaffold.

    From our library, several compounds showed activity against #HCV, #HSV, #influenza, and #RSV. One uracil-based analogue stood out by inhibiting multiple viruses like #flu and HCV. Modeling suggests it “locks” the viral active site instead of being incorporated into RNA.

    What really surprised us: nucleobases with known antiviral effects (like NHC from molnupiravir) didn’t work in our scaffold—but unmodified uracil did. The scaffold itself changes how these molecules behave.

    Encouragingly, these compounds phosphorylate efficiently in cells without needing prodrugs, don't inhibit human polymerases, and our #synthesis is efficient: 28 pyrimidine and 35 purine analogues from just two intermediates in under 10 steps.

    Huge thanks to all collaborators and colleagues who made this work possible!

    pubs.acs.org/doi/10.1021/acs.j

    J. Med. Chem. 2026, 69, 5, 5501–5539.

    #research #science #drug

  24. Excited to share our paper in Journal of Medicinal #Chemistry exploring carbobicyclic nucleoside analogues as potential #antivirals!

    We swapped the ribose oxygen for a carbon in nucleoside analogues and explored this novel scaffold.

    From our library, several compounds showed activity against #HCV, #HSV, #influenza, and #RSV. One uracil-based analogue stood out by inhibiting multiple viruses like #flu and HCV. Modeling suggests it “locks” the viral active site instead of being incorporated into RNA.

    What really surprised us: nucleobases with known antiviral effects (like NHC from molnupiravir) didn’t work in our scaffold—but unmodified uracil did. The scaffold itself changes how these molecules behave.

    Encouragingly, these compounds phosphorylate efficiently in cells without needing prodrugs, don't inhibit human polymerases, and our #synthesis is efficient: 28 pyrimidine and 35 purine analogues from just two intermediates in under 10 steps.

    Huge thanks to all collaborators and colleagues who made this work possible!

    pubs.acs.org/doi/10.1021/acs.j

    J. Med. Chem. 2026, 69, 5, 5501–5539.

    #research #science #drug

  25. Insightful talk by Clemens Richert at #Biochemistry2026. He talked about his group’s work on optimized #antivirals. He gave exciting insights into the optimization of prodrugs of nucleotides #ProTides.

    #Biochemistry #Chemistry #ChemBio #Virus #DrugDiscovery
    CC: @gdch, @GDCh_BioChem

  26. Insightful talk by Clemens Richert at #Biochemistry2026. He talked about his group’s work on optimized #antivirals. He gave exciting insights into the optimization of prodrugs of nucleotides #ProTides.

    #Biochemistry #Chemistry #ChemBio #Virus #DrugDiscovery
    CC: @gdch, @GDCh_BioChem

  27. Insightful talk by Clemens Richert at #Biochemistry2026. He talked about his group’s work on optimized #antivirals. He gave exciting insights into the optimization of prodrugs of nucleotides #ProTides.

    #Biochemistry #Chemistry #ChemBio #Virus #DrugDiscovery
    CC: @gdch, @GDCh_BioChem

  28. Insightful talk by Clemens Richert at #Biochemistry2026. He talked about his group’s work on optimized #antivirals. He gave exciting insights into the optimization of prodrugs of nucleotides #ProTides.

    #Biochemistry #Chemistry #ChemBio #Virus #DrugDiscovery
    CC: @gdch, @GDCh_BioChem

  29. Interesting talk by Foteini Skoulikopoulou of the group of Zach Armstrong of the @LED3hub at #NWOCHAINS. She talked about her research into the synthesis of stable 9-O-acetylated sialic acid mimics with potential applications as #antivirals.

    #glycotime #Chemistry #ChemBio

  30. Interesting talk by Foteini Skoulikopoulou of the group of Zach Armstrong of the @LED3hub at #NWOCHAINS. She talked about her research into the synthesis of stable 9-O-acetylated sialic acid mimics with potential applications as #antivirals.

    #glycotime #Chemistry #ChemBio

  31. Interesting talk by Foteini Skoulikopoulou of the group of Zach Armstrong of the @LED3hub at #NWOCHAINS. She talked about her research into the synthesis of stable 9-O-acetylated sialic acid mimics with potential applications as #antivirals.

    #glycotime #Chemistry #ChemBio

  32. @DenisCOVIDinfoguy

    Thanks for being the #Covid guy and doing all the hard background #research for your posts. To add my lazy two-cents worth I recently got a real bad dose of Covid and it was the worst “dose of flu” that I have suffered.

    It was about four days before I even thought to test myself feeling bad enough for Hospital. Stupid, because I am elderly and have heart problems.

    #Antivirals made me feel a lot better.

    I’m fully #vaccinated but the latest strain finally got through! Picked up at a local shopping centre.

    I plan to start wearing an #N95 each time I visit a large shopping centre now, just like the old days. 👍🧐🧐🧐

  33. @DenisCOVIDinfoguy

    Thanks for being the #Covid guy and doing all the hard background #research for your posts. To add my lazy two-cents worth I recently got a real bad dose of Covid and it was the worst “dose of flu” that I have suffered.

    It was about four days before I even thought to test myself feeling bad enough for Hospital. Stupid, because I am elderly and have heart problems.

    #Antivirals made me feel a lot better.

    I’m fully #vaccinated but the latest strain finally got through! Picked up at a local shopping centre.

    I plan to start wearing an #N95 each time I visit a large shopping centre now, just like the old days. 👍🧐🧐🧐

  34. @DenisCOVIDinfoguy

    Thanks for being the #Covid guy and doing all the hard background #research for your posts. To add my lazy two-cents worth I recently got a real bad dose of Covid and it was the worst “dose of flu” that I have suffered.

    It was about four days before I even thought to test myself feeling bad enough for Hospital. Stupid, because I am elderly and have heart problems.

    #Antivirals made me feel a lot better.

    I’m fully #vaccinated but the latest strain finally got through! Picked up at a local shopping centre.

    I plan to start wearing an #N95 each time I visit a large shopping centre now, just like the old days. 👍🧐🧐🧐